The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
12-Mar-99
$3.1 billion
Target:
M&G Group plc
Acquiror:
Prudential Corp. plc
Advised M&G Group on the sale of the company for cash to Prudential, the United Kingdom’s largest life insurer and fund manager.
22-Sep-00
$750 million
Target:
AerFi Group plc
Acquiror:
debis AirFinance (subsidiary of Daimler Chrysler AG)
Advised AerFi on its sale to debis AirFinance .
31-Jan-03
$NA
Target:
Charles Schwab Europe
Acquiror:
Barclays PLC
Advised The Charles Schwab Corporation on the sale of its British pound sterling brokerage business, to Barclays PLC.
13-Sep-05
$NA
Target:
AEA Technology plc
Acquiror:
Coller Capital
Advised AEA Technology plc, a UK provider of Rail and Environmental services, on the sale of a portfolio of non-core businesses to Coller Capital. The sale formed part of a wider financial restructuring plan
19-May-06
$1.4 billion
Target:
London Stock Exchange Group plc
Acquiror:
The Nasdaq Stock Market, Inc.
(25.1% stake)
Advised The Nasdaq Stock Market, Inc., the largest electronic equity securities market in the United States, on the acquisition of a 25.1% stake in London Stock Exchange plc
02-Jul-08
$NA
Target:
NewSmith Capital
Acquiror:
UniCredit SpA
Advised NewSmith Capital, an independent investment management group, on a strategic agreement with UniCredit whereby UniCredit will acquire NewSmith’s Financial Products credit advisory business, assume a 5% stake in NewSmith Capital and become an investor in NewSmith funds
18-May-09
$114 million
Target:
Close Brothers Corporate Finance Holdings Ltd.
Acquiror:
Daiwa Securities SMBC Europe Ltd.
Advised Close Brothers Group plc, an independent financial services group, on the sale of its corporate finance subsidiary to Daiwa Securities SMBC Europe Ltd.
06-Apr-10
$153 million
Target:
Virgin Money Holdings (UK) Limited
Acquiror:
W.L. Ross & Co. LLC
Advised Virgin Money Holdings (UK) Limited, Virgin Group’s financial services arm, on the structuring of an investment of £100m from WL Ross & Co.
28-Jun-10
$1.3 billion
Target:
Guinness Peat Group plc
Advised GPG plc, a listed investment company, on potential restructuring alternatives
12-Nov-10
$NA
Target:
Money Controls (subsidiary of Coin Acceptors, Inc.)
Acquiror:
Crane Co.
Advised Coin Acceptors, Inc. (“CoinCo”), a privately-owned US-based manufacturer of payment solutions for the automated point-of-sale industry, on the sale of its UK-based Money Controls subsidiary to Crane Co., a diversified manufacturer of highly engineered industrial products
26-Nov-10
$118 million
Target:
Healthcare Australia
Acquiror:
Healthcare Locums
Advised CHAMP Private Equity on the sale of Healthcare Australia, a leading provider of nursing agency staff to public and private health institutions in Australia, to Healthcare Locums, a healthcare recruitment agency based in the UK
13-Dec-10
$256 million
Target:
Maxinutrition Group Holdings Limited
Acquiror:
GlaxoSmithKline Plc
Advised GlaxoSmithKline Plc, the UK listed international pharmaceutical and consumer company, on its acquisition of Maxinutrition Group Holdings Limited, a UK based sports nutrition business, from Darwin Private Equity
21-Mar-11
$NA
Target:
Close Brothers Cayman Limited
Acquiror:
Intertrust Group Holdings SA
Advised Close Brothers plc, an independent financial services group, on the sale of its Cayman based offshore business to Intertrust Group Holdings SA
16-Sep-11
$NA
Target:
Mako Global Derivatives Executive LLP
Acquiror:
Mako Executive Directors and Staff
Advised Close Brothers Group plc, an independent financial services group, on the sale of its 49.9% stake in Mako Global, a market maker in exchange traded derivatives, to Mako’s management
17-Nov-11
$1.5 billion
Target:
Northern Rock
Acquiror:
Virgin Money
Advised Virgin Money, a financial services provider, on the acquisition of Northern Rock, a UK retail mortgage and savings bank, from UK Financial Investments Ltd, which manages the UK Government’s investments in financial institutions
30-Oct-12
$834 million
Target:
Investments of AP Alternative Assets, L.P.
Acquiror:
Athene Holding Ltd.
Advised the Special Committee of the Conflicts Committee of the Board of Directors of Athene Holding Ltd. in connection with the purchase of non-cash investment assets of AP Alternative Assets L.P.
20-May-13
$8.5 billion
Target:
Warner Chilcott, plc
Acquiror:
Actavis, Inc.
Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc
31-Jul-13
$NA
Target:
CPP Group plc
Advised on the comprehensive restructuring of its balance sheet, including sale of the US business, terming out the existing RCF and creation of additional liquidity by the long term deferral of business partner payments
26-Jun-14
$2.7 billion
Target:
Frank Russell Company
Acquiror:
London Stock Exchange Group plc
Advised LSEG on the proposed acquisition of Frank Russell Company, the number one provider of benchmarks to US-focused equity funds and a leading provider of multi-asset class investment solutions, from Northwestern Mutual Life Insurance Company, including acting as Joint Sponsor to LSEG on its $1.6 billion rights issue
02-Jun-15
$NA
Target:
Portfolio of GlaxoSmithKline plc consumer and OTC brands
Acquiror:
Perrigo Company plc
Advised GlaxoSmithKline plc, a leading British pharmaceutical company, on the disposal of a portfolio of consumer and OTC brands to Omega Pharma NV, a subsidiary of Perrigo Company plc
27-Jul-15
$40.5 billion
Target:
Allergan Generics
Acquiror:
Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
01-Dec-15
$NA
Target:
Allied Healthcare
Acquiror:
AURELIUS Investments
Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments
04-Oct-16
$223 million
Target:
US rights to Toprol-XL (AstraZeneca)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
05-Oct-16
$NA
Target:
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
05-Oct-16
$775 million
Target:
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)